XML 35 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
The Company and Summary of Significant Accounting Policies (Details Textual)
 9 Months Ended 12 Months Ended
Sep. 30, 2017
USD ($)
Patients
shares
Dec. 31, 2016
USD ($)
shares
Dec. 31, 2015
USD ($)
shares
Aug. 21, 2017
USD ($)
Jan. 11, 2017
USD ($)
Company And Summary Of Significant Accounting Policies Table [Line Items]          
Revenues $ 0        
Common stock, shares issued | shares 11,750,744 9,082,366      
Proceeds from sale of common stock $ 6,515,000        
Concentrations of credit risk $ 0        
Excess tax benefits from share-based payments   $ 0 $ 0    
Number of shares withhold to satisfy statutory income tax withholding obligations | shares   0 0    
At the Market Offering under Sales Agreement          
Company And Summary Of Significant Accounting Policies Table [Line Items]          
Aggregate offering price of common stock authorized       $ 10,200,000 $ 7,300,000
Increase in the maximum aggregate offering price of common stock authorized       $ 2,900,000  
Common stock, shares issued | shares 2,653,440        
Proceeds from sale of common stock $ 6,500,000        
Net proceeds from issuance of common stock $ 6,100,000        
Phase 3 | BEST Trial          
Company And Summary Of Significant Accounting Policies Table [Line Items]          
Number of patients | Patients 2,708        
Phase 2B | GENETIC-AF Trial          
Company And Summary Of Significant Accounting Policies Table [Line Items]          
Number of patients company plans to enroll | Patients 267        
Trial endpoint, term 168 days